SCHEMBL1010562

SCHEMBL1010562

COC(=O)C(CC1CCCC1)n1ncc(Cl)c(Cl)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
RAB9A P51151 5/20 0.47
HTT P42858 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
MAPT P10636 4/20 0.47
MITF O75030 3/20 0.47
LMNA P02545 3/20 0.47
MDM2 Q00987 2/20 0.47
RECQL P46063 1/20 0.47
NPC1 O15118 5/20 0.44
PAX8 Q06710 2/20 0.41
NPBWR1 P48145 1/20 0.40
KAT2B Q92831 1/20 0.39
GCK P35557 5/20 0.37
NPSR1 Q6W5P4 4/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
GPR35 Q9HC97 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1009040 0.82 GCK (0.35) ALDH1A1RAB9AHTTSMN1; SMN2MAPT
SCHEMBL29452012 0.80 ALDH1A1 (0.43) ALDH1A1RAB9AHTTSMN1; SMN2MAPT
SCHEMBL1008225 0.80 LMNA (0.36) HTTSMN1; SMN2LMNANPBWR1KAT2B
SCHEMBL1065040 0.79 L3MBTL1 (0.40) ALDH1A1MAPTGCKNPSR1POLB
SCHEMBL1009410 0.78 GCK (0.37) GCKCNR2
SCHEMBL2196324 0.77 GCK (0.41) LMNAGCKMEN1KMT2A
SCHEMBL2196327 0.77 GCK (0.41) LMNAGCKMEN1KMT2A
SCHEMBL1008591 0.77 GCK (0.37) RAB9ALMNANPC1NPBWR1GCK
SCHEMBL1007711 0.77 GCK (0.36) GCKOPRK1
SCHEMBL1008851 0.76 GRN (0.38) ALDH1A1RAB9AHTTSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK ALDH1A1 1059/4885RAB9A 3487/4885HTT 3381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.